Filtered By:
Cancer: Prostate Cancer
Drug: Xgeva
This page shows you your search results in order of date.
Order by Relevance | Date
Total 51 results found since Jan 2013.
Nanoparticle-mediated synergistic drug combination for treating bone metastasis
J Control Release. 2023 Apr 12:S0168-3659(23)00269-9. doi: 10.1016/j.jconrel.2023.04.019. Online ahead of print.ABSTRACTBone metastasis at an advanced disease stage is common in most solid tumors and is untreatable. Overexpression of receptor activator of nuclear factor κB ligand (RANKL) in tumor-bone marrow microenvironment drives a vicious cycle of tumor progression and bone resorption. Biodegradable nanoparticles (NPs), designed to localize in the tumor tissue in bone marrow, were evaluated in a prostate cancer model of bone metastasis. The combination treatment, encapsulating docetaxel, an anticancer drug (TXT-NPs), a...
Source: Cancer Control - April 14, 2023 Category: Cancer & Oncology Authors: Mohammed Tanjimur Rahman Youzhi Kaung Logan Shannon Charlie Androjna Nima Sharifi Vinod Labhasetwar Source Type: research
Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Survey among Urologists in Switzerland, Germany, and Austria
J Clin Med. 2023 Jan 13;12(2):638. doi: 10.3390/jcm12020638.ABSTRACTMedication-related osteonecrosis of the jaw (MRONJ) is a potentially preventable adverse side effect of mainly antiresorptive drugs. MRONJ is expected to become a growing clinical problem due to the aging population and the increasing number of patients requiring antiresorptive agents. Knowledge and awareness about MRONJ and elimination of the oral and dental risk factors before starting antiresorptive therapy (AR) are fundamental to reducing the incidence of MRONJ. In urology, ARs are used primarily in patients suffering from bone metastases due to prosta...
Source: Clinical Prostate Cancer - January 21, 2023 Category: Cancer & Oncology Authors: Salvatore Calderaro Kathrin Bausch C éline Tourbier Christian Wetterauer Florian M Thieringer Britt-Isabelle Berg Source Type: research
Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo
CONCLUSIONS: Patients with mCRPC with bone metastasis received osteoprotection in 2/3 of cases. Of these, 2/3 received denosumab and 1/3 received a bisphosphonate. The majority of patients were also treated with calcium and vitamin D. According to guideline recommendations regarding osteoprotection in mCRPC patients with bone metastasis, our RWD data showed some lack of guideline adherence.PMID:36423613 | DOI:10.1055/a-1949-7814
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: Christian Doehn J örg Klier Manfred Johannsen Rolf Eichenauer Robert Sch önfelder Allessandro Romagnolo Stephan Reese Christian Nitz Andreas Jaeger Claus Fieseler Marcus Burkert-Scholz Horst Brenneis Manfred Binder Maike Beuke J örg Schröder Elke Hemp Source Type: research
Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo
CONCLUSION: Patients with nmHSPC received osteoprotection in 1/5 of patients. Of these, 3/4 received denosumab and 1/4 received a bisphosphonate. The majority of patients were additionally treated with calcium and vitamin D. In our study, osteoprotection in patients with nmHSPC was rather an exception.PMID:36423612 | DOI:10.1055/a-1954-6826
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: J örg Klier Frank K önig Robert Sch önfelder Rolf Eichenauer Manfred Johannsen Maike Beuke Manfred Binder Horst Brenneis Marcus Burkert-Scholz Claus Fieseler Andreas Jaeger Christian Nitz Stephan Reese Allesandro Romagnolo J örg Schröder Elke Hempel Source Type: research
Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo
CONCLUSIONS: Patients with mCRPC with bone metastasis received osteoprotection in 2/3 of cases. Of these, 2/3 received denosumab and 1/3 received a bisphosphonate. The majority of patients were also treated with calcium and vitamin D. According to guideline recommendations regarding osteoprotection in mCRPC patients with bone metastasis, our RWD data showed some lack of guideline adherence.PMID:36423613 | DOI:10.1055/a-1949-7814
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: Christian Doehn J örg Klier Manfred Johannsen Rolf Eichenauer Robert Sch önfelder Allessandro Romagnolo Stephan Reese Christian Nitz Andreas Jaeger Claus Fieseler Marcus Burkert-Scholz Horst Brenneis Manfred Binder Maike Beuke J örg Schröder Elke Hemp Source Type: research
Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo
CONCLUSION: Patients with nmHSPC received osteoprotection in 1/5 of patients. Of these, 3/4 received denosumab and 1/4 received a bisphosphonate. The majority of patients were additionally treated with calcium and vitamin D. In our study, osteoprotection in patients with nmHSPC was rather an exception.PMID:36423612 | DOI:10.1055/a-1954-6826
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: J örg Klier Frank K önig Robert Sch önfelder Rolf Eichenauer Manfred Johannsen Maike Beuke Manfred Binder Horst Brenneis Marcus Burkert-Scholz Claus Fieseler Andreas Jaeger Christian Nitz Stephan Reese Allesandro Romagnolo J örg Schröder Elke Hempel Source Type: research
Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo
CONCLUSIONS: Patients with mCRPC with bone metastasis received osteoprotection in 2/3 of cases. Of these, 2/3 received denosumab and 1/3 received a bisphosphonate. The majority of patients were also treated with calcium and vitamin D. According to guideline recommendations regarding osteoprotection in mCRPC patients with bone metastasis, our RWD data showed some lack of guideline adherence.PMID:36423613 | DOI:10.1055/a-1949-7814
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: Christian Doehn J örg Klier Manfred Johannsen Rolf Eichenauer Robert Sch önfelder Allessandro Romagnolo Stephan Reese Christian Nitz Andreas Jaeger Claus Fieseler Marcus Burkert-Scholz Horst Brenneis Manfred Binder Maike Beuke J örg Schröder Elke Hemp Source Type: research
Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo
CONCLUSION: Patients with nmHSPC received osteoprotection in 1/5 of patients. Of these, 3/4 received denosumab and 1/4 received a bisphosphonate. The majority of patients were additionally treated with calcium and vitamin D. In our study, osteoprotection in patients with nmHSPC was rather an exception.PMID:36423612 | DOI:10.1055/a-1954-6826
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: J örg Klier Frank K önig Robert Sch önfelder Rolf Eichenauer Manfred Johannsen Maike Beuke Manfred Binder Horst Brenneis Marcus Burkert-Scholz Claus Fieseler Andreas Jaeger Christian Nitz Stephan Reese Allesandro Romagnolo J örg Schröder Elke Hempel Source Type: research
Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo
CONCLUSIONS: Patients with mCRPC with bone metastasis received osteoprotection in 2/3 of cases. Of these, 2/3 received denosumab and 1/3 received a bisphosphonate. The majority of patients were also treated with calcium and vitamin D. According to guideline recommendations regarding osteoprotection in mCRPC patients with bone metastasis, our RWD data showed some lack of guideline adherence.PMID:36423613 | DOI:10.1055/a-1949-7814
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: Christian Doehn J örg Klier Manfred Johannsen Rolf Eichenauer Robert Sch önfelder Allessandro Romagnolo Stephan Reese Christian Nitz Andreas Jaeger Claus Fieseler Marcus Burkert-Scholz Horst Brenneis Manfred Binder Maike Beuke J örg Schröder Elke Hemp Source Type: research
Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo
CONCLUSION: Patients with nmHSPC received osteoprotection in 1/5 of patients. Of these, 3/4 received denosumab and 1/4 received a bisphosphonate. The majority of patients were additionally treated with calcium and vitamin D. In our study, osteoprotection in patients with nmHSPC was rather an exception.PMID:36423612 | DOI:10.1055/a-1954-6826
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: J örg Klier Frank K önig Robert Sch önfelder Rolf Eichenauer Manfred Johannsen Maike Beuke Manfred Binder Horst Brenneis Marcus Burkert-Scholz Claus Fieseler Andreas Jaeger Christian Nitz Stephan Reese Allesandro Romagnolo J örg Schröder Elke Hempel Source Type: research
Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo
CONCLUSIONS: Patients with mCRPC with bone metastasis received osteoprotection in 2/3 of cases. Of these, 2/3 received denosumab and 1/3 received a bisphosphonate. The majority of patients were also treated with calcium and vitamin D. According to guideline recommendations regarding osteoprotection in mCRPC patients with bone metastasis, our RWD data showed some lack of guideline adherence.PMID:36423613 | DOI:10.1055/a-1949-7814
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: Christian Doehn J örg Klier Manfred Johannsen Rolf Eichenauer Robert Sch önfelder Allessandro Romagnolo Stephan Reese Christian Nitz Andreas Jaeger Claus Fieseler Marcus Burkert-Scholz Horst Brenneis Manfred Binder Maike Beuke J örg Schröder Elke Hemp Source Type: research
Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo
CONCLUSION: Patients with nmHSPC received osteoprotection in 1/5 of patients. Of these, 3/4 received denosumab and 1/4 received a bisphosphonate. The majority of patients were additionally treated with calcium and vitamin D. In our study, osteoprotection in patients with nmHSPC was rather an exception.PMID:36423612 | DOI:10.1055/a-1954-6826
Source: Aktuelle Urologie - November 24, 2022 Category: Urology & Nephrology Authors: J örg Klier Frank K önig Robert Sch önfelder Rolf Eichenauer Manfred Johannsen Maike Beuke Manfred Binder Horst Brenneis Marcus Burkert-Scholz Claus Fieseler Andreas Jaeger Christian Nitz Stephan Reese Allesandro Romagnolo J örg Schröder Elke Hempel Source Type: research
